A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Active:	Yes
Cancer Type:	Breast Cancer	NCT ID:	NCT06492616
Trial Phases:	Phase III	Protocol IDs:	STML-ELA-0422 (primary) NCI-2025-00399
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Stemline Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06492616

Summary

The primary goal of this study is to evaluate the effectiveness of elacestrant versus
standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive
(ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high
risk of recurrence.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.